NCI-006

Overview

NCI-006 is an orally active lactate dehydrogenase ( LDH ) inhibitor (LDHA IC 50 = 0.06 μM; LDHB IC 50 = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 ( HY-112037 ) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model.

Application

Products | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > NF-κB | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Signaling Pathways > Lactate Dehydrogenase | Products > Signaling Pathways > Reactive Oxygen Species (ROS) | Products > Signaling Pathways > Apoptosis

Product Information

• Catalog No.: HY-176798
• CAS No.: 1964516-64-0
• Molecular Formula: C31H24F2N4O4S3
• Molecular Weight: 650.74
• Purity: 98.73%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source